Case study
Bridge the Gap Between Prediction and Proof
Your virtual cell models generate target predictions at scale. Embyr delivers experimental validation at the same speed—testing dozens to hundreds of targets in parallel with complete mechanistic insight.
Validated 67 AI-predicted targets in 12 weeks | 3.8M single-cell profiles | 34% confirmation rate
“We had 87 computational predictions and could only afford to validate 10. If we chose wrong, we'd lose a year."
— CSO, Series B Oncology Company
The Computational-Experimental Bottleneck
You've invested in virtual cell modeling, AI-driven target prediction, or computational biology platforms. Your models are generating promising target hypotheses faster than ever. But there's a problem.
Traditional experimental validation can't keep pace.
Sequential testing means choosing 5-10 targets and hoping you picked the right ones. Fragmented CRO workflows create 3-6 month gaps between validation stages. And investors won't commit based on computational predictions alone—they need experimental proof.
By the time you validate your first batch of targets, your computational team has generated three more rounds of predictions. The backlog grows. Pipeline decisions stall. And you're burning capital on validation approaches designed for a pre-AI era.
Validate Your Entire Target Portfolio. In Parallel.
Embyr's Discovery Engine is purpose-built to validate computational predictions at the scale and speed modern drug discovery demands. We don't just test whether your AI got it right—we deliver complete mechanism of action characterization for every validated target.
Three-Phase Validation Workflow
Phase 1: Computational Integration
We integrate your virtual cell predictions with human genetics, clinical data, and proprietary knowledge graphs to refine target prioritization and identify potential validation challenges before experiments begin.
Phase 2: Massively Parallel Functional Validation
Our Perturb-seq platform tests dozens to hundreds of targets simultaneously using proprietary CRISPR modules across disease-relevant cellular models. Generate millions of single-cell profiles capturing both predicted and unexpected target effects.
Phase 3: Mechanistic Reconstruction
Deep probabilistic models reconstruct complete pathways—confirming predictions, revealing alternative mechanisms, identifying off-target risks, and discovering combination opportunities your virtual cell models couldn't predict.
Why Parallel Validation Changes Everything
Traditional: Pick 10 targets → Wait 6 months → Validate 3 → Pick 10 more → Repeat
18 months to validate 20 targets
Embyr: Test all 67 targets simultaneously → Complete results in 12 weeks
Validate your entire portfolio in one cycle.
Driven by passion
We're not here to follow trends—we're here to build something timeless. With a blend of creativity, strategy, and heart, we help ideas come to life. Every project we take on is an opportunity to learn, grow, and do something meaningful. We treat our clients like partners and our work like craft.
Their attention to detail and commitment to quality truly stood out. We’ve already recommended them to others.
—Former Customer